000838796 000__ 04786cam\a2200553Ii\4500
000838796 001__ 838796
000838796 005__ 20230306144654.0
000838796 006__ m\\\\\o\\d\\\\\\\\
000838796 007__ cr\un\nnnunnun
000838796 008__ 180427s2018\\\\sz\a\\\\ob\\\\001\0\eng\d
000838796 019__ $$a1033573764$$a1033644061$$a1033781773$$a1034554470$$a1038441961
000838796 020__ $$a9783319782386$$q(electronic book)
000838796 020__ $$a331978238X$$q(electronic book)
000838796 020__ $$z9783319782379
000838796 020__ $$z3319782371
000838796 0247_ $$a10.1007/978-3-319-78238-6$$2doi
000838796 035__ $$aSP(OCoLC)on1032611990
000838796 035__ $$aSP(OCoLC)1032611990$$z(OCoLC)1033573764$$z(OCoLC)1033644061$$z(OCoLC)1033781773$$z(OCoLC)1034554470$$z(OCoLC)1038441961
000838796 040__ $$aN$T$$beng$$erda$$epn$$cN$T$$dN$T$$dGW5XE$$dEBLCP$$dYDX$$dAZU$$dOCLCQ$$dCOO$$dOCLCQ$$dUPM$$dUAB$$dOCLCF$$dOCLCQ
000838796 049__ $$aISEA
000838796 050_4 $$aRC280.L9
000838796 08204 $$a616.99/446$$223
000838796 24500 $$aResistance to ibritumomab in lymphoma /$$cMakoto Hosono, Jean-François Chatal, editors.
000838796 264_1 $$aCham :$$bSpringer,$$c[2018]
000838796 264_4 $$c©2018
000838796 300__ $$a1 online resource :$$billustrations.
000838796 336__ $$atext$$btxt$$2rdacontent
000838796 337__ $$acomputer$$bc$$2rdamedia
000838796 338__ $$aonline resource$$bcr$$2rdacarrier
000838796 347__ $$atext file$$bPDF$$2rda
000838796 4901_ $$aResistance to targeted anti-cancer therapeutics ;$$vvolume 18
000838796 504__ $$aIncludes bibliographical references and index.
000838796 5050_ $$6880-01$$aIntro; "Resistance to Targeted Anti-Cancer Therapeutics": Aims and Scope; Preface; Biography of Series Editor; Acknowledgments; Contents; Clinical Use and Efficacy of Ibritumomab in B Cell Lymphoma; 1 Introduction; 2 Characteristics of Zevalin; 3 Treatment Schedule and Dosage of Zevalin; 4 Patient Eligibility; 5 Zevalin in Relapse or Refractory Patients; 6 Zevalin in Frontline Therapy; 7 Toxicities and Safety Profile; 8 Factor Associated with Effects of Zevalin; 9 Future Aspects; References; Biology and Pathology of B-Cell Lymphoma; 1 Introduction; 2 Cellular Origin of B-Cell Lymphomas.
000838796 5058_ $$a3 Features of Ibritumomab4 A Model of Theranostic Approach; 5 Enhancing Efficacy of Ibritumomab Tiuxetan; 6 Conclusion; References; Radiological Evaluation of Response and Resistance of Ibritumomab; 1 Introduction; 2 Evaluation of FDG-PET/CT for Monitoring the Response to RIT; 2.1 FDG-PET/CT Imaging; 3 Summary of the Results; 4 Discussion; 5 Conclusions; References; Characteristics of Ibritumomab as Radionuclide Therapy Agent; 1 Introduction; 2 CD 20: B-Cell Antigen; 3 mAb Targeting CD20; 4 Ibritumomab Tiuxetan Coupled with Radioisotopes; 4.1 Ibritumomab; 4.2 Tiuxetan; 4.3 Radionuclides.
000838796 5058_ $$a5 Yttrium-90 (90Y)6 Indium-111 (111In); 7 Preclinical Investigation of 90Y-/111In-Ibritumomab Tiuxetan; 7.1 In Vitro Studies; 7.2 Ex Vivo/In Vivo Studies; 8 Imaging and Therapy Protocol; 8.1 Preparation of 90Y-Ibritumomab Tiuxetan; 8.2 Schedule of 90Y-Ibritumomab Tiuxetan Therapy; 9 Perspectives and Conclusion; References; Resistance and Heterogeneity of Intratumoral Antibody Distribution; 1 Introduction; 2 SPECT/CT and PET/CT System; 3 Statistical Approach Taken to Characterize Lesion's Uptake; 4 Resistance and Heterogeneity of Intratumoral Antibody Distribution.
000838796 5058_ $$a5 Conclusions and PerspectivesReferences; Radiation Dosimetry in Ibritumomab Therapy; 1 Introduction; 2 Activity Escalation Trial and Dose Escalation Trial; 3 Dosimetry for Molecular Radiotherapy; 3.1 Quantification of Pharmacokinetics; 3.2 Kinetic Model; 3.3 Prediction of Pharmacokinetics During Therapy; 3.4 Absorbed Dose Calculations; 3.5 Treatment Planning; 3.6 Treatment and Quality Control Measurements; 3.7 Conclusion; 4 Dosimetry for Ibritumomab Tiuxetan; 5 Treatment Planning for [90Y]Ibritumomab Tiuxetan; 6 Conclusion and Outlook; References.
000838796 506__ $$aAccess limited to authorized users.
000838796 520__ $$aThis volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.
000838796 588__ $$aOnline resource; title from PDF title page (viewed  April 30, 2018).
000838796 650_0 $$aLymphomas$$xTreatment.
000838796 650_0 $$aDrug resistance in cancer cells.
000838796 7001_ $$aHosono, Makoto,$$eeditor.
000838796 7001_ $$aChatal, Jean-François,$$d1939-$$eeditor.
000838796 77608 $$iPrint version:$$tResistance to ibritumomab in lymphoma.$$dCham : Springer, [2018]$$z3319782371$$z9783319782379$$w(OCoLC)1024253614
000838796 830_0 $$aResistance to targeted anti-cancer therapeutics ;$$vv. 18.
000838796 852__ $$bebk
000838796 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-319-78238-6$$zOnline Access$$91397441.1
000838796 909CO $$ooai:library.usi.edu:838796$$pGLOBAL_SET
000838796 980__ $$aEBOOK
000838796 980__ $$aBIB
000838796 982__ $$aEbook
000838796 983__ $$aOnline
000838796 994__ $$a92$$bISE